Combivent inhalers dispense a combination of albuterol and ipratropium bromide, according to Boehringer Ingelheim Pharmaceuticals. The two medicines are bronchodilators that work to keep airways open, and doctors commonly prescribe them to those with chronic obstructive pulmonary disease, or COPD.
As of 2013, the manufacturer discontinued production and sale of traditional Combivent Inhalation Aerosol inhalers due to the admittance of harmful chlorofluorocarbons or CFCs into the environment, according to U.S. Food and Drug Administration. CFCs pushed the two medicines out of the inhalers, but they also contribute to deterioration of the Earth's ozone layer. Combivent Respimat serves as the replacement for the aerosol inhalers and utilizes a spraying technology to release albuterol and ipratropium into the airway.